The invention is directed to compounds of Formula I: wherein Z, X, JR and Ware set forth in
the specification, as well as Solvates, hydrates, tautomers and pharmaceutically acceptable …

2,466,420 A 4, 1949 Hagemeyer et al. 3,226,394 A 12/1965 Schipper 4,551,540 A 11, 1985
Hechenbleikner et al. 5, 190,541 A 3, 1993 Abele et al. 5,474,765 A 12/1995 Thorpe …

0 [1*]/C ([2*])= N/N ([12*]) C (= S) CN1C ([3*])([4*]) C ([5*])([6*])[Y]([7*]) C ([8*])([9*]) C1
([10*])[11*] Chemical compound [1*]/C ([2*])= N/N ([12*]) C (= S) CN1C ([3*])([4*]) C …

3,717,579 A* 2, 1973 Hofmann et al............. 514,352 NW 3,862,152 A 1/1975 Kuwada et al.
X 4,172,947 A 10/1979 Warner, Jr. et al. R2 4,186,199 A 1, 1980 Glamkowski et al. y1 …

3,717,579 A 2f1973 Hoffman et al. 3,862,152 A 1/1975 Kuwada et al. 4,172,947 A 10/1979
Warner, Jr. et al. 4,186,199 A 1, 1980 Glamkowski et al. 5,258,357 A 11/1993 Muenster et al …

A is phenyl, naphthyl or biphenyl, each of which may be optionally Substituted with one or
more of-C alkyl, amino, aminoalkyl, hydroxyalkyl, alkoxy alkyl, Sulfonamidoalkyl …

The present invention provides compounds that are gamma secretase modulators and are
therefore useful for the treat ment of diseases treatable by modulation of gamma secretase …

The invention is directed to compounds of Formula I: wherein Z, X, J, Rand Ware set forth in
the specification, as well as Solvates, hydrates, tautomers and pharmaceutically acceptable …

LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C ([C@ H](C (= O)
N [C@@ H]([C@@ H](C) CC) C (= O) N [C@@ H](CO) C (= O) N [C@ H](CCC (N)= O) C …

The invention is directed to compounds of Formula I: wherein Z, X, JR and Ware set forth in
the specification, as well as Solvates, hydrates, tautomers and pharmaceutically acceptable …